Researchers develop nanohybrid vehicle to optimally deliver drugs into the human body

UTEP researchers develop nanohybrid vehicle to optimally deliver drugs into the human body
Mahesh Narayan, Ph.D., along with and Sreeprasad Sreenivasan, Ph.D. (not pictured), has developed a nanohybrid vehicle that can be used to optimally deliver drugs into the human body. Both researchers are faculty members in in UTEP's Department of Chemistry and Biochemistry. Credit: Mahesh Narayan.

Researchers in The University of Texas at El Paso's Department of Chemistry and Biochemistry have developed a nanohybrid vehicle that can be used to optimally deliver drugs into the human body.

The research was published in April 2020 in ACS Applied Materials & Interfaces. Leading the study are Mahesh Narayan, Ph.D., professor, and Sreeprasad Sreenivasan, Ph.D., assistant professor, both from the Department of Chemistry and Biochemistry and the Border Biomedical Research Center (BBRC) in UTEP's College of Science.

Drug candidates that show promise against a particular disease often are toxic to other cell types. One such is the polyphenol ellagic acid (EA). This antioxidant, derived from nature, demonstrates the potential to mitigate pathologies including Parkinson's and Alzheimer's diseases. To selectively use EA in the brain against neurodegenerative disorders requires that its cytotoxic potential be reduced and only its anti-oxidant potential be exploited. Narayan, Sreenivasan and colleagues created a nanohybrid vehicle to circumvent this problem.

"We are very excited about the new drug delivery materials developed by Drs. Narayan and Sreenivasan," said Robert Kirken, Ph.D., dean of UTEP's College of Science. "This platform allows for molecules to be impregnated into the material so that the drug can more specifically target the tumor or other tissue site, thus increasing the beneficial effects of the drug while reducing its ."

The researchers discovered that encapsulating EA in chitosan, a sugar, reduces its inherent cytotoxicity while enhancing its anti-oxidant properties. The chitosan shell, which makes up the hard outer skeleton of shellfish, also permits EA delivery via a rapid burst phase and a relatively slow phase. This further enhances the drug delivery because the nanohybrid vehicle is uniquely suited for drug release over extended time periods.

"This work creates a new type of bio-friendly drug-delivery vehicle made of recyclable materials," Narayan said. "The other special feature of this vehicle is that it can deliver the drug via two mechanisms: one rapid and the other a slow-release."

Other project collaborators include UTEP doctoral student Jyoti Ahlawat, who led the research project under the supervision of her mentors; Eva Deemer, Ph.D., of UTEP's Department of Materials Science and Engineering; and Rabin Neupane, a graduate student in the department of industrial pharmacy at the University of Toledo.

Narayan's laboratory focuses on mitigating oxidative stress induced by neurotoxins as a means to prevent neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. Sreenivasan's lab works to bridge and interface chemistry, materials physics, and biological sciences to develop uniquely designed quantum structures and devices.


Explore further

Inhaled nanoparticles could treat lung cancer

More information: Jyoti Ahlawat et al, Chitosan–Ellagic Acid Nanohybrid for Mitigating Rotenone-induced Oxidative Stress, ACS Applied Materials & Interfaces (2020). DOI: 10.1021/acsami.9b21215
Citation: Researchers develop nanohybrid vehicle to optimally deliver drugs into the human body (2020, April 24) retrieved 13 July 2020 from https://phys.org/news/2020-04-nanohybrid-vehicle-optimally-drugs-human.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
397 shares

Feedback to editors

User comments